Last reviewed · How we verify
FBX-101
At a glance
| Generic name | FBX-101 |
|---|---|
| Also known as | AAVrh.10-hGALC |
| Sponsor | Forge Biologics, Inc |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT (PHASE1, PHASE2)
- Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
- Gene Transfer Clinical Trial for Krabbe Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FBX-101 CI brief — competitive landscape report
- FBX-101 updates RSS · CI watch RSS
- Forge Biologics, Inc portfolio CI